521 related articles for article (PubMed ID: 25721083)
1. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
2. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
[TBL] [Abstract][Full Text] [Related]
3. Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.
Lee SC; Min HY; Jung HJ; Park KH; Hyun SY; Cho J; Woo JK; Kwon SJ; Lee HJ; Johnson FM; Lee HY
Oncogene; 2016 Oct; 35(42):5515-5526. PubMed ID: 27086926
[TBL] [Abstract][Full Text] [Related]
4. Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.
Min HY; Lee SC; Woo JK; Jung HJ; Park KH; Jeong HM; Hyun SY; Cho J; Lee W; Park JE; Kwon SJ; Lee HJ; Ni X; Shin YK; Johnson FM; Duvic M; Lee HY
Clin Cancer Res; 2017 Mar; 23(5):1299-1311. PubMed ID: 27582487
[No Abstract] [Full Text] [Related]
5. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Imre G; Gekeler V; Leja A; Beckers T; Boehm M
Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Peled N; Wynes MW; Ikeda N; Ohira T; Yoshida K; Qian J; Ilouze M; Brenner R; Kato Y; Mascaux C; Hirsch FR
Cell Oncol (Dordr); 2013 Jul; 36(4):277-88. PubMed ID: 23619944
[TBL] [Abstract][Full Text] [Related]
9. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer.
Min HY; Yun HJ; Lee JS; Lee HJ; Cho J; Jang HJ; Park SH; Liu D; Oh SH; Lee JJ; Wistuba II; Lee HY
Mol Cancer; 2015 Jun; 14():113. PubMed ID: 26041671
[TBL] [Abstract][Full Text] [Related]
10. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
[TBL] [Abstract][Full Text] [Related]
11. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
Zhao FY; Han J; Chen XW; Wang J; Wang XD; Sun JG; Chen ZT
Int J Mol Med; 2016 Jul; 38(1):183-91. PubMed ID: 27177336
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
13. Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.
Alam MM; Lee SC; Jung Y; Yun HJ; Min HY; Lee HJ; Pham PC; Moon J; Kwon DI; Lim B; Suh YG; Lee J; Lee HY
Oncotarget; 2015 Dec; 6(38):40598-610. PubMed ID: 26515601
[TBL] [Abstract][Full Text] [Related]
14. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
16. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
17. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
18. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.
Iwasa T; Okamoto I; Suzuki M; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2009 Aug; 15(16):5117-25. PubMed ID: 19671857
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
